CC Chemokine Receptor Type 5 Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The CC Chemokine Receptor Type 5 Market Expected To Become By 2029 Compared With Its 2025 Level?

The market for cc chemokine receptor type 5 has experienced swift expansion recently. This market is projected to expand from $1.4 billion in 2024 to $1.54 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.1%. Historically, this growth has been driven by factors such as government funding, collaborations in research and development, public health initiatives, partnerships between public and private entities, and the initial discovery of CCR5.

The cc chemokine receptor type 5 market size is anticipated to undergo significant expansion in the coming years, with projections indicating it will climb to $2.26 billion in 2029, achieving a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period can be attributed to the prevalence of HIV or AIDS, improvements in healthcare infrastructure, various economic incentives, the escalating demand for healthcare services, and general economic growth. Noteworthy trends identified for this period include expanding research efforts in cancer treatment, the ongoing development of combination therapies, advancements in pharmaceutical manufacturing, the establishment of strategic collaborations and partnerships, and the broadened scope of clinical trials.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18290&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The CC Chemokine Receptor Type 5 Industry?

The CC chemokine receptor type 5 market is projected to expand due to the increasing occurrence of chronic diseases. Chronic diseases are long-term medical conditions, including heart disease, diabetes, and arthritis, which progress slowly and frequently demand continuous management. The rising prevalence of these diseases is attributed to aging populations and an increase in lifestyle-related risk factors such as poor diet, physical inactivity, and obesity. CC Chemokine Receptor Type 5 (CCR5) is crucial in chronic diseases like human immunodeficiency virus (HIV), acting as a coreceptor that allows the virus to enter and infect immune cells, thereby playing a key role in the disease’s progression. For instance, in October 2023, according to the Joint United Nations Programme on HIV/AIDS, a Switzerland-based, comprehensive global program to prevent HIV infection, approximately 38.7 million people were infected with HIV in 2021. This figure rose to 39.0 million people in 2022, with 1.3 million newly infected people in the year 2022. Consequently, the increasing prevalence of chronic diseases is driving the growth of the CC chemokine receptor type 5 market.

How Is The CC Chemokine Receptor Type 5 Market Segmented?

The cc chemokine receptor type 5market covered in this report is segmented –

1) By Type: BMS-813160; AG-1105; CCL-14; DS-001; Other Types

2) By Distribution Channel: Hospitals; Clinics; Online Pharmacies; Retail Pharmacies

3) By Application: Infectious Disease; Gastrointestinal; Immunology; Oncology; Other Applications

4) By End User: Research Institutes; Pharmaceutical Companies; Healthcare Facilities

Subsegments:

1) By BMS-813160: CCR5 Antagonist For HIV Treatment; CCR5 Antagonist For Inflammatory Diseases

2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders; CCR5 Antagonist For Cancer Therapy

3) By CCL-14: Chemokine Ligand For Targeted Therapy; CCL-14 For Immune Modulation

4) By DS-001: CCR5 Inhibitor For Cancer Treatment; DS-001 For Inflammatory Disease Management

5) By Other Types: Novel CCR5 Antagonists; Dual-Target CCR5 Antagonists

What Key Innovation Trends Are Fueling Advancements In The CC Chemokine Receptor Type 5 Market?

Leading firms within the CC chemokine receptor type 5 market are concentrating on creating novel medications, specifically CCR5 antagonists, to achieve an edge over competitors. A CCR5 antagonist functions by obstructing the CCR5 receptor found on immune cells, thus impeding specific pathogens like HIV from attaching and penetrating these cells, which in turn prevents infection and adjusts immune responses. An example of this is seen in February 2024, when CytoDyn Inc., a US-based biotechnology firm, declared that the FDA had removed the clinical hold previously placed on leronlimab. The company now possesses authorization to proceed with its intended HIV clinical trial, aiming to examine leronlimab’s effects on chronic inflammation. Leronlimab, also identified as PRO 140 and a CCR5 antagonist, holds potential for diverse therapeutic uses because of its capability to address numerous health issues, and is currently under investigation for several conditions, notably HIV and cancer.

Who Are The Key Multinational Companies Dominating The CC Chemokine Receptor Type 5 Market?

Major companies operating in the cc chemokine receptor type 5 market are Pfizer Inc., Sorrento Therapeutics, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Avexa Limited, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences Inc., Vertex Pharmaceuticals, Ono Pharmaceutical Co Ltd, Abcam Limited, BioLegend Inc., R&D Systems Inc, American Gene Technologies International Inc, NSJ Bioreagents, Cytodyn Inc., Affinity Biosciences

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Which Region Is Projected To Lead The CC Chemokine Receptor Type 5 Market During The Forecast Period?

North America was the largest region in the CC chemokine receptor type 5 market in 2024. The regions covered in the CC chemokine receptor type 5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The CC Chemokine Receptor Type 5 Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18290&type=smp

Browse Through More Reports Similar to the Global CC Chemokine Receptor Type 5 Market 2025, By The Business Research Company

Chimeric Antigen Receptor T Car T Cells Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chimeric-antigen-receptor-t-car-t-cells-global-market-report

Angiotensin Receptor Blockers Arbs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Glp 1 Receptor Agonist Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795